Categories: Tech

Diginex Announces Execution of Warrants Agreement, Bonus Share Issuance and Cancelation of EGM

 | Source: Diginex Limited

LONDON, July 25, 2025 (GLOBE NEWSWIRE) — Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced that on July 22, 2025 Rhino Ventures Limited exercised warrants, with an exercise price of $5.13 per share, to purchase 2,250,000 ordinary shares of Diginex. The total exercise price of US$11,542,500 has been delivered in full to the Company. The warrants exercised by Rhino Ventures Limited were due to expire on 23rd July 2025.

The board of directors of Diginex (the “Board”) has determined to terminate its plans for an 8 shares for 1 share forward stock split in favour of a bonus share issuance which is expected to be declared and distributed during the third quarter of 2025. Accordingly, the Board has determined to cancel Diginex’s extraordinary general meeting that was scheduled to take place on July 29, 2025. 

About Diginex

Diginex Limited (Nasdaq: DGNX; ISIN KYG286871044), headquartered in London, is a sustainable RegTech business that empowers businesses and governments to streamline ESG, climate, and supply chain data collection and reporting. The Company utilizes blockchain, AI, machine learning and data analysis technology to lead change and increase transparency in corporate regulatory reporting and sustainable finance. Diginex’s products and services solutions enable companies to collect, evaluate and share sustainability data through easy-to-use software. 

The award-winning diginexESG platform supports 19 global frameworks, including GRI (the “Global Reporting Initiative”), SASB (the “Sustainability Accounting Standards Board”), and TCFD (the “Task Force on Climate-related Financial Disclosures”). Clients benefit from end-to-end support, ranging from materiality assessments and data management to stakeholder engagement, report generation and an ESG Ratings Support Service.

For more information, please visit the Company’s website:

https://www.diginex.com/.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the SEC.

Diginex
Investor Relations
Email: ir@diginex.com 

IR Contact – Europe
Anna Höffken
Phone: +49.40.609186.0
Email: diginex@kirchhoff.de 

IR Contact – US
Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: jian.lin@llyc.global 

IR Contact – Asia
Shelly Cheng
Strategic Financial Relations Ltd.
Phone: +852 2864 4857
Email: sprg_diginex@sprg.com.hk 

GlobeNews Wire

Recent Posts

Curonix Strengthens Executive Leadership with Appointment of Leading Medical Device Executive Russell Fleeger as Chief Financial Officer to Drive Next Stage of Growth

POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”),…

56 minutes ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine ophthalmic solution) 1.44%…

56 minutes ago

Survey from White Clay Finds Two-thirds of Customers Do Not Feel Truly Known by Their Primary Financial Institution

Data shows relationship gap between financial institutions and their customers is holding strong LOUISVILLE, Ky.--(BUSINESS…

58 minutes ago

Motus Recognized as a 2025 Inc. Power Partner Award Winner

The annual list recognizes the leading B2B companies that have proven track records of supporting…

58 minutes ago

INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community

Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug discovery for priority…

59 minutes ago

Metabolon Powers Largest-Ever Veteran Metabolomics Study with Global Discovery Panel

Metabolon to Support Landmark Million Veteran Program 62,000-sample Dataset Advancing Veteran Health and Multiomics Research…

59 minutes ago